T 1086/24 (Sustained-release dosage forms of ruxolitinib / INCYTE) of 09.06.2026
- European Case Law Identifier
- ECLI:EP:BA:2026:T108624.20260609
- Date of decision
- 9 June 2026
- Case number
- T 1086/24
- Online on
- 28 August 2026
- Petition for review of
- -
- Application number
- 13798840.8
- IPC class
- A61K 31/4045A61K 9/20
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- SUSTAINED-RELEASE DOSAGE FORMS OF RUXOLITINIB
- Applicant name
- Incyte Holdings Corporation
- Opponent name
- Maiwald GmbH
Teva Pharmaceutical Industries Ltd.
STADA Arzneimittel AG
Alfred E. Tiefenbacher (GmbH & Co. KG) - Board
- 3.3.07
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 123(2)European Patent Convention Art 54(3)European Patent Convention Art 56Rules of procedure of the Boards of Appeal 2020 Art 012(4)
- Keywords
- Amendments - added subject-matter (no)
Novelty - (yes)
Inventive step - (yes) - Catchword
- -
- Cited cases
- T 0136/24
- Citing cases
- -
Order
For these reasons it is decided that:
The decision under appeal is set aside
The case is remitted to the opposition division with the order to maintain the patent on the basis of the claims of the main request filed as auxiliary request 14 on 26 January 2024 and a description to be adapted thereto.